Abstract:Background: Lung cancer is a leading cause of cancer death globally. Platinum-based chemotherapeutic medications are essential for treating advanced NSCLC, despite that drug resistance severely limits its effectiveness. Objective: In this study, we investigated the cytotoxic effect of metformin on cisplatin-resistant NSCLC cells (A549/DDP) and its potential mechanisms. Methods: Anti-lung cancer efficacy of metformin, cisplatin, and metformin combined with cisplatin was examined in A549 and A549/DDP cells. The cell counting kit-8 (CCK-8) assay was applied for measuring cell proliferation. CalcuSyn software was used to calculate the combination index and estimate the synergistic effect of metformin and cisplatin on cell proliferation. The cell apoptosis was analyzed by flow cytometry and the expression of apoptosis-related proteins, Bcl-2, Bax and caspase-3 were analyzed using Western blot. Futhermore, the expression of key nucleotide excision repair (NER) proteins, ERCC1, XPF, and XPA, was also analyzed using Western blot. Results: We found that metformin had dose-dependent antiproliferative effects on A549/DDP and A549 cells. The combination of metformin and cisplatin had higher effectiveness in inhibiting A549/DDP and A549 cell growth than either of the two drugs alone. Flow cytometry analysis indicated that the combined treatment could cause more cell apoptosis than the single-drug treatment. Consistently, the combined treatment decreased the expression of Bcl-2 protein and elevated the expression of Bax, and cleaved caspase-3 proteins. The expression level of ERCC1, XPF, and XPA proteins were lower in the combined treatment than in either of metformin and cisplatin treatment alone. Conclusions: Our study suggested that metformin and cisplatin had synergistic antitumorigenic effects in A549/DDP cells. The combination of cisplatin and metformin could be promising drug candidates to sensitize cisplatin-induced apoptosis through regulating nucleotide excision repair pathways in lung cancer.

Metformin modified chitosan as a multi-functional adjuvant to enhance cisplatin-based tumor chemotherapy efficacy

Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy

Delivery of Platinum (II) Drugs with Bulky Ligands in Trans-Geometry for Overcoming Cisplatin Drug Resistance.

Metformin Inhibited Esophageal Squamous Cell Carcinoma Proliferation in Vitro and in Vivo and Enhanced the Anti-Cancer Effect of Cisplatin

Metformin Sensitizes the Response of Oral Squamous Cell Carcinoma to Cisplatin Treatment Through Inhibition of NF-κB/HIF-1α Signal Axis

Metformin Sensitizes Cisplatin-induced Apoptosis Through Regulating Nucleotide Excision Repair Pathway in Cisplatin-resistant Human Lung Cancer Cells

Metformin Reverses The Drug Resistance Of Cisplatin In Irradiated Cne-1 Human Nasopharyngeal Carcinoma Cells Through Pecam-1 Mediated Mrps Down-Regulation

Metformin mitigates cisplatin-induced ovarian damage through inhibiting the pyroptosis of granulosa cells via ROS/TXNIP/NLRP3 signaling pathway

Reversing multi-drug resistance by polymeric metformin to enhance antitumor efficacy of chemotherapy

Co-delivery of Polymeric Metformin and Cisplatin by Self-Assembled Core-Membrane Nanoparticles to Treat Non-Small Cell Lung Cancer

Metformin Potentiates the Anticancer Activities of Gemcitabine and Cisplatin Against Cholangiocarcinoma Cells in Vitro and in Vivo

Metformin Enhances Anti-Cancer Effects of Cisplatin in Meningioma Through AMPK-mTOR Signaling Pathways

Integrative analyses of biomarkers and pathways for metformin reversing cisplatin resistance in head and neck squamous cell carcinoma cells.

Metformin overcomes chemoresistance by regulating stemness via KLF4 in oral squamous cell carcinoma

Metformin combined with cisplatin reduces anticancer activity via ATM/CHK2-dependent upregulation of Rad51 pathway in ovarian cancer

Co-delivery of metformin enhances the anti-multidrug resistant tumor effect of doxorubicin by improving hypoxic tumor microenvironment.

Enhancement of Cisplatin Efficacy by Lipid-Cao2 Nanocarrier-Mediated Comprehensive Modulation of the Tumor Microenvironment.

Metformin-Loaded Chitosan Hydrogels Suppress Bladder Tumor Growth in an Orthotopic Mouse Model via Intravesical Administration

Combining Disulfiram and Poly(l-Glutamic Acid)-Cisplatin Conjugates for Combating Cisplatin Resistance.

Supramolecular Cisplatin-Vorinostat Nanodrug for Overcoming Drug Resistance in Cancer Synergistic Therapy

Reregulated Mitochondrial Dysfunction Reverses Cisplatin Resistance Microenvironment in Colorectal Cancer